Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Eisai Co., Ltd. (OTC: ESALF).

Full DD Report for ESALF

You must become a subscriber to view this report.

Recent News from (OTC: ESALF)

Eisai And Merck & Co. Announce China NMPA Approval of First Approval for LENVIMA (Lenvatinib) for Treatment of Unresectable HCC
First Approval for LENVIMA in China and First New Therapy for the First-line Treatment of Unresectable HCC Approved in China in a Decade TOKYO, Sept 5, 2018 - (JCN Newswire) - Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Ca...
Source: ACN Newswire
Date: September, 05 2018 02:28
Eisai Receives Approval for Partial Label Change for Vascular Embolization Device DC Bead
TOKYO, Sept 3, 2018 - (JCN Newswire) - Eisai Co., Ltd. announced that it has received approval for a partial label change for the vascular embolization device DC Bead (specially controlled medical device) in Japan. The product is to be used for transcatheter arterial embolization in patients w...
Source: ACN Newswire
Date: September, 03 2018 03:05
Eisai's LENVIMA (LENVATINIB) Capsules Approved for First-Line Treatment of Unresectable Hepatocellular Carcinoma (HCC) in South Korea
TOKYO, Aug 30, 2018 - (JCN Newswire) - Eisai Co., Ltd. announced that its South Korea subsidiary Eisai Korea Inc. received approval for the kinase inhibitor LENVIMA (lenvatinib mesylate) as a single agent for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC)...
Source: ACN Newswire
Date: August, 29 2018 21:36
Biogen and Eisai Report Data from Long-Term Extension Phase 1b Study of Investigational Alzheimer's Disease Treatment Aducanumab
Data Includes Additional Analyses of Long-Term Extension Phase 1b Study With Titration Cohort at 36 Months and Fixed-Dose Cohorts at 48 Months TOKYO, Aug 29, 2018 - (JCN Newswire) - Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. announced results from a recent analysis of the ongoing long-term ex...
Source: ACN Newswire
Date: August, 28 2018 22:25
Eisai: Long-Term Cardiovascular Outcomes Data for Anti-Obesity Agent BELVIQ
Presented at The European Society of Cardiology and Published in the New England Journal of Medicine TOKYO, Aug 28, 2018 - (JCN Newswire) - The average change in weight from baseline was -4.2 kg with BELVIQ and -1.4 kg with placebo, translating to a 2.8 kg greater net weight loss with BELVIQ...
Source: ACN Newswire
Date: August, 27 2018 21:11
Eisai: European Commission Grants Marketing Authorization for LENVIMA (Lenvatinib)
As First-Line Treatment in Adults with Advanced or Unresectable Hepatocellular Carcinoma TOKYO, Aug 23, 2018 - (JCN Newswire) - Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced today that the European Commissi...
Source: ACN Newswire
Date: August, 22 2018 20:00
Eisai Co., Ltd. ADR 2018 Q1 - Results - Earnings Call Slides
The following slide deck was published by Eisai Co., Ltd. ADR in conjunction with their 2018 Q1 earnings Read more ...
Source: SeekingAlpha
Date: August, 01 2018 14:48
Eisai Signs Collaboration Agreement for Anti-Obesity Agent Lorcaserin in China to CY Biotech
TOKYO, July 31, 2018 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into an agreement to grant exclusive development and marketing rights for its anti-obesity agent lorcaserin hydrochloride (generic name, product name in the United States: BELVIQ, product name for once-...
Source: ACN Newswire
Date: July, 31 2018 02:13
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Announce U.S. FDA Grants Breakthrough Therapy Designation for LENVIMA
In Combination with KEYTRUDA as Therapy for Previously Treated Patients with Advanced and/or Metastatic non-MSI-H/pMMR Endometrial Carcinoma TOKYO, July 31, 2018 - (JCN Newswire) - Eisai Co., Ltd. and Merck & Co., Inc. Kenilworth, N.J., U.S.A. (NYSE:MRK), known as MSD outside the United ...
Source: ACN Newswire
Date: July, 30 2018 22:27
Biogen And Eisai: Let The Alzheimer's Arguing Commence
Well, the tease is over: Biogen (BIIB) and Eisai (ESALY) (ESALF) have released data on their Alzheimer's antibody, BAN2401. And the situation is messy, as many had feared. The top-line results are mostly positive, but there are several confounding factors that make them a matter of argument ...
Source: SeekingAlpha
Date: July, 27 2018 06:10


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ESALF.

About Eisai Co., Ltd. (OTC: ESALF)

Logo for Eisai Co., Ltd. (OTC: ESALF)

Eisai Co. and its subsidiaries are engaged in the manufacture and sale of pharmaceuticals, consumer health care products, diagnostic products, chemicals and food additives, and animal health products. Co. s products include antiallergy agent, osteoporosis treatment, gastritis/gastric ulcer medication, vitamins, food preservative, flavoring agent, and sweetening material. Co. is also engaged in the manufacture and sale of pharmaceutical production system and machines.


Contact Information



Current Management

  • Haruo Naito / President, CEO
  • Hideaki Matsui / CFO

Current Share Structure

  • Market Cap: $15,762,530,735 - 03/09/2018
  • Issue and Outstanding: 296,566,900 - 11/30/2011


Daily Technical Chart for (OTC: ESALF)

Daily Technical Chart for (OTC: ESALF)

Stay tuned for daily updates and more on (OTC: ESALF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: ESALF)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

DD Report



Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ESALF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ESALF and does not buy, sell, or trade any shares of ESALF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: